6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
Evidence-based guidance on semaglutide (Ozempic) dosing considerations for Hispanic and Latino patients, including pharmacogenomic factors, insulin resistance phenotypes, and ethnicity-stratified trial data.
A deep look at semaglutide 0.5 to 2.0 mg efficacy in East Asian patients, covering ethnicity-stratified trial subgroups, pharmacogenomics, BMI thresholds, and clinical dosing considerations prepared by the HealthRX.com Editorial Team.
Evidence-based guide to semaglutide (Ozempic) dosing considerations for East Asian patients, including pharmacogenomic factors, lower BMI thresholds, and clinical trial subgroup data.
A clinician-focused review of semaglutide 0.5 to 2.0 mg efficacy differences in Hispanic and Latino patients, covering ethnicity-stratified RCT subgroup data, pharmacogenomics, insulin resistance phenotypes, and dosing considerations.
Evidence-based review of semaglutide (Ozempic) efficacy differences in South Asian populations, including pharmacogenomic factors, BMI thresholds, and clinical trial subgroup data.
How semaglutide (Ozempic) safety, dosing, and side effects differ in South Asian populations, including pharmacogenomic factors, cardiovascular considerations, and clinical monitoring recommendations.